TP53 and endometrial cancer: With the development of multiomics technology, The Cancer Genome Atlas (TCGA) proposed the molecular classification of endometrial cancer in 2013 [9], which contains four main subtypes: (1) POLE-hypermutation; (2) MSI-H/dMMR; (3) copy number low (CNL)/NSMP; and (4) copy number high (CNH)/p53abn, closely related to the prognosis of patients, among which, POLE-hypermutation has the best prognosis, followed by MSI and CNL, and in contrast, CNH endometrial cancer accompanied by frequent p53 mutations has the worst prognosis.